The Front Room — a clinical regulatory commons
RSS
← Back to The Docket
DEC 1 2026
UPCOMING · 63 DAYS TO PDUFA

Vertex Pharmaceuticals Incorporated — povetacicept $VRTX

for IgA nephropathy

BLA · Priority Review · Accelerated Approval

About

IgA nephropathy is a kidney disease in which the immune system inflames the glomeruli, the tiny filtering units that clean the blood, and aggressive cases can also attack the liver, skin, and heart. Povetacicept is a lab-made protein that binds and blocks two immune signals, BLyS and APRIL, that drive B cells to produce antibodies. Because those signals help generate the faulty IgA antibodies that clog the kidney, blocking them may reduce protein in the urine and help preserve kidney function.

Pivotal trial

NCT06564142 Phase 3 active not recruiting NCT06564142

The purpose of this study is to evaluate the efficacy of povetacicept in adult participants compared with placebo in reducing proteinuria and preserving renal function.

Source: ClinicalTrials.gov

Also in development